The latest update is out from D.Western Therapeutics Institute, Inc. ( (JP:4576) ).
D.Western Therapeutics Institute, Inc. has entered a joint research agreement with Professor Hitoshi Kasai of Tohoku University to develop next-generation drug formulations for eye diseases. This collaboration aims to address the increasing patient needs for effective treatments by enhancing drug efficacy and intraocular penetration, without impacting the company’s earnings forecast for the fiscal year ending December 2025.
More about D.Western Therapeutics Institute, Inc.
D.Western Therapeutics Institute, Inc. operates in the pharmaceutical industry with a focus on ophthalmology. The company is engaged in drug discovery activities aimed at creating new drug candidates, particularly for eye diseases with high unmet medical needs such as retinal diseases and cataracts.
YTD Price Performance: -51.34%
Technical Sentiment Signal: Strong Buy
Current Market Cap: €29.35M
Find detailed analytics on 4576 stock on TipRanks’ Stock Analysis page.